The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | BELLWAVE-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve CLL/SLL
Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, introduces BELLWAVE-011 (NCT06136559), a global Phase III trial comparing nemtabrutinib, an irreversible non-covalent BTK inhibitor (BTKi), to investigator’s choice of ibrutinib or acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So it’s an ongoing randomized trial that is going to evaluate the efficacy and the safety of nemtabrutinib, which is an irreversible non-covalent binding BTKi, in comparison to the choice of the investigator, which can decide whether to use ibrutinib or acalabrutinib in patients who are treatment naive CLL or SLL. The study is going to be quite big study because we plan to randomize 1200 patients and it’s going to be in six continents...
So it’s an ongoing randomized trial that is going to evaluate the efficacy and the safety of nemtabrutinib, which is an irreversible non-covalent binding BTKi, in comparison to the choice of the investigator, which can decide whether to use ibrutinib or acalabrutinib in patients who are treatment naive CLL or SLL. The study is going to be quite big study because we plan to randomize 1200 patients and it’s going to be in six continents. So it will be around the globe, both in North America, South America, in Asia, in Europe, in Australia, as well as in Israel. And it’s going to give us an answer regarding the use of BTK as a monotherapy or as a continuous therapy, both in terms of efficacy, because we are going to compare the non-covalent to the covalent BTKi as well as in terms of safety and intolerance.
Read more...
Disclosures
Grant or Consultations: Abbvie, Astra Zeneca, Roche, Janssen, Novartis, Takeda, Sanofi.
